Home CompaniesLupin Pharma Lupin partners Medis for distribution of NaMuscla in Central, Eastern Europe

Lupin partners Medis for distribution of NaMuscla in Central, Eastern Europe

by admin
0 comment
Lupin, Pharma, Goa, USFDA, Sales, Profit, Business, Deal , Manufacturing , Plant ,EIR

Summary :

Drug firm Lupin on Wednesday said it has entered into a distribution pact with Slovenia-based Medis for its orphan drug NaMuscla.

As part of the agreement, Medis will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries, Lupin said in a statement.

NaMuscla is the first and only licensed product for this indication.

Lupin, Pharma, Goa, USFDA, Sales, Profit, Business, Deal , Manufacturing , Plant ,EIR

 Lupin Pharma

Under the agreement, Medis will initially focus on the commercialisation of NaMuscla in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase.

Lupin will continue commercialisation of NaMuscla in Germany, France, and the UK.

“The distribution agreement represents an important milestone for Lupin as we continue the roll out of NaMuscla across Europe. We know that collaborating with partners which are highly focused in their territories means patients receive medicines in the most efficient way,” said Thierry Volle, President EMEA, Lupin.

NDM disorders are a group of rare, inherited neuromuscular disorders which are characterised by the inability of muscles to relax following voluntary contraction.

NaMuscla reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients.

NaMuscla, which has been designated orphan drug status, received EU marketing authorisation in December 2018.

According to the US health regulator, USFDA, ‘orphan drug’ is a drug or biologic that is used for the prevention, diagnosis, or treatment of diseases or conditions affecting fewer than 2 lakh people.

It is also defined as a drug or biologic that is intended for diseases or conditions affecting 2 lakh or more people, or for a vaccine, diagnostic drug, or preventive drug to be administered to 2 lakh or more people per year, where the drug will not be profitable within 7 years following the FDA approval.

 

For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:

Website : https://www.chemrobotics.com/ (Agrochemical Databases)

Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Our Company

ChemRobotics is a global Scientific, Technical & Business data intelligence company, especially in the field of Pharmaceutical, Agrochemical, Veterinary and Fine Chemical.

ChemRobotics Times

Subscribe ChemRobotics for the latest updates in the Pharmaceutical, Agrochemical, Veterinary, and Fine Chemical Industries

Laest News

ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved. 

Designed and Developed by Ample eBusiness